(4 mg/kg on 4 consecutive days). Four patients with chronic
In approximately half of allogeneic BMT recipients tetamyeloid leukaemia also received one infusion of daunorubnus toxoid (TT) antibody concentrations decline to nonicin, 60 mg/m 2 and splenic irradiation. The patient receivdetectable 3-5 or non-protective 6 levels during long-term foling a transplant for aplastic anaemia was conditioned with low-up. The risk for tetanus is generally low, but it is cyclophosphamide 50 mg/kg on 4 consecutive days and accepted worldwide that the population should be protected total nodal irradiation 8.0 Gy in four fractions on 2 conagainst tetanus. 7 TT vaccine is a protein antigen which is secutive days. Acute GVHD was defined according to immunogenic, with vaccination schedules starting in early Thomas et al 9 and treated with methylprednisolone, starting infancy. 8 with a dose of 2 mg/kg/day or 10-15 mg/kg/day, depending In order to find out if early vaccination of adult alloon the severity of GVHD. Chronic GVHD was defined according to Shulman et al 10 and treated with methylprednisolone alone or in combination with azathioprine the day before marrow harvesting. (Figure 1 ). One 0.5 ml dose of the vaccine well with those of the functional, neutralizing in vivo test contained 5 limits of flocculation (Lf) units of tetanus toxin mice. However, the PHA test tends to overestimate antioid adsorbed onto aluminium phosphate (0.5 mg). The vacbody concentrations in sera with low titres. 12 Therefore, the cine was administered intramuscularly. Three doses of inminimal protective level was set to 0.1 HU/ml instead of activated poliomyelitis vaccine (Polio Novum, RIVM, the conventional 0.01 IU/ml used for in vivo toxin neuBilthoven, The Netherlands) were given with the same tralization assays. A tetanus antibody concentration of у1 schedule as TT vaccine. At the time of the first dose of TT HU/ml is considered to provide long-lasting immunity. 13 vaccine, patients received Haemophilus influenzae type Seroconversion from seronegative to seropositive or a fourb polysaccharide-diphtheria toxoid conjugate vaccine fold or higher increase in the tetanus antibody concentration (ProHIBIT; Connaught Laboratories, Swiftwater, PA, were used as criteria for response.
Statistical methods
Fisher's exact test was used to compare the frequency of individuals in the two vaccination groups with the anti-tetanus antibody concentrations and fold responses indicated. t-test for two independent samples with log-transformed data was used to compare the geometric mean antibody concentrations between the two vaccination groups. Paired t-test was used when the geometric mean concentrations (GMC) pre-and post-vaccination were compared. The correlations between the log-transformed pre-and post-trans- correlation coefficient.
antibodies were significantly higher than the respective prevaccination GMCs, except for the first vaccine dose in the early group.
After the first TT vaccine dose, four-fold increases in the tetanus antibody concentration were more often seen in the late group patients; otherwise responses were not significantly different in the two vaccination groups (Table 2) . Six recipients (one in the early group, five in the late group) had a no-detectable tetanus antibody concentration before starting the vaccination program. Four of these six recipients (67%) responded to the first vaccine dose.
After the first, second, and third dose, 20 out of 22, 21 antibody concentration of у0.1 HU/ml. After the third dose, 14 out of 17 early group and 15 out of 17 late group patients had antibody concentrations of у1 HU/ml.
Results
Twenty-two months after completing the vaccination program, every patient in both vaccination groups had an Prior to BMT, the GMC of anti-tetanus antibodies of the antibody concentration of у0.1 HU/ml. patients (1.15 HU/ml) did not differ from that of the donors Acute GVHD did not impair the immunization response. (1.37 HU/ml). Thirty-three out of 35 patients (94%) and 36
Patients with or without chronic GVHD had no significant out of 39 donors (92%) had a TT antibody concentration differences in the GMCs of anti-TT antibodies before startof у0.1 HU/ml. Twenty-four patients and 25 donors had ing and after completing the vaccination program. In the an antibody concentration of у1 HU/ml. In the BMT late group, chronic GVHD tended to lower the proportion recipients, the GMC of tetanus antibodies decreased conof patients with four-fold responses (a four-fold response tinuously after BMT (Figure 2 ). Prior to vaccination, 19 out in 11 out of 12 recipients without chronic GVHD and in of 21 early group patients (90%) and 14 out of 20 late two out of five recipients with chronic GVHD, P = 0.05). group patients (70%) had a tetanus antibody concentration
At approximately 1 year after BMT the early group of у0.1 HU/ml. The GMC of the anti-tetanus antibodies patients had a higher GMC of anti-tetanus antibodies than was higher, although not significantly, in the early group the unvaccinated late group patients: 0.73 HU/ml in the patients at 6 months after BMT than in the late group early group at 14 months and 0.20 HU/ml in the late group patients at 18 months after BMT. After the first tetanus at 1 year after BMT (P = 0.04). There were no significant vaccine dose and prior to and after the second and third differences in the GMCs of the tetanus antibodies between doses the GMCs of the anti-tetanus antibodies were not the two vaccination groups at any time after completing significantly different in the two vaccination groups ( Table 2 ). The post-vaccination GMCs of the anti-tetanus the three-dose vaccination program (Figure 3 ). Thirty-six b P Ͻ 0.05 when geometric mean concentrations (GMC) were compared before and after vaccination. c P Ͻ 0.01 when GMCs were compared before and after vaccination. d P Ͻ 0.001 when GMCs were compared before and after vaccination. e P = 0.02 when four-fold response rates in the two vaccination groups were compared. positive T cells after intensive chemotherapy correlates inversely with the age of the patient.
14 Three of the few previous tetanus immunity and vaccination trials among BMT recipients included children 4,6,15 and one included autologous transplantations and allogeneic transplantations with T cell depletion, in addition to allogeneic unmanipulated transplantations. 15 According to Lum, 1 the immune recovery rate of recipients of allogeneic unmanipulated marrow grafts is between that of autologous recipients and recipients of allogeneic T cell-depleted marrow grafts.
In this study, a PHA test with a known minimal protec- with our results.
6,15
Prior to BMT the vast majority of the present patients had an anti-TT antibody concentration considered protecmonths after BMT, the GMCs of tetanus antibodies were not significantly different in the early and late groups tive (у0.1 HU/ml). At 18 months after BMT 70% of the patients still not vaccinated had a protective antibody con-(1.47 HU/ml vs 1.91 HU/ml). Chronic GVHD had no influence on the ability to retain tetanus antibody concencentration. Guinan et al 15 measured protective, though often low, tetanus antibody concentrations in all BMT recipients trations after vaccination in the early group. In the late group the influence of chronic GVHD on the antibody con-12-24 months after BMT, whereas only approximately 50% of the recipients in some other studies have had a centrations could not be examined since only one patient had chronic GVHD and serum samples у32 months after protective antibody concentration 13-98 months after BMT. 6,16 Heterogeneity of the patient populations in the BMT. different studies with regard to age and bone marrow manipulation may explain these differences.
Correlation of antibody responses to tetanus toxoid
The present results show that the GMCs of the anti-TT vaccinations with pretransplant antibody concentrations antibodies after each vaccination given at 6, 8 and 14 months or at 18, 20 and 26 months after BMT were not Until 6 months after BMT, the tetanus antibody concentration in the patient correlated with his/her own pretranssignificantly different in the two vaccination groups. However, after the first dose of tetanus vaccine the post-vacciplant level (Pearson's correlation coefficient 0.46-0.72, P Ͻ 0.01). In the early group the patient's antibody concennation GMC of the anti-TT antibodies was significantly higher than the prevaccination GMC in patients vaccinated tration after the first tetanus vaccine dose correlated with his/her own pretransplant level (Pearson's correlation coefat 18 months after BMT, not in the early vaccination group. This difference in response is in line with previous findings ficient 0.86, P Ͻ 0.001) but not thereafter. In the late group patients, pre-or post-vaccination TT antibody concenaccording to which T cell-dependent antigens elicit antibody responses to recall antigens late, у1 year after trations had no correlation with the patient's own pretransplant antibody concentration. In the early group the BMT 5,15,17,18 but not early after unmanipulated 19 or T celldepleted 20 BMT. Only if the donor or both the donor and patient's tetanus antibody concentration did not correlate with the donor's antibody concentration at any time. In the recipient have been immunized with TT vaccine before BMT, has the patient been able to respond to one to two late group prior to the first vaccination, the patient's tetanus antibody concentration did not correlate with the donor's doses of TT vaccine during the 1st year after BMT. 19, 20 However, the present results showed that the BMT recipiantibody concentration, but it did after the first and second vaccinations and just before the second and third vaccients who received tetanus vaccine at 6 and 8 months after BMT were able to respond to the second dose. nations (Pearson's correlation coefficient 0.57-0.67, P Ͻ 0.05). After the third vaccine dose correlation with the The late group patients without chronic GVHD had more four-fold responses to TT vaccination than the patients with donor disappeared.
chronic GVHD. The present study suggests that BMT patients with chronic GVHD have moderate, but not such high responses to TT vaccination as recipients without Discussion GVHD. Lum et al 3, 4 showed that the patients without chronic GVHD retained their anti-TT antibodies better than We prospectively randomized adult allogeneic BMT recipients to receive TT vaccine at 6, 8 and 14 or at 18, 20 and those with chronic GVHD in cross-sectional studies in which each marrow recipient was studied only once at vary-26 months after BMT. The results show that good antibody responses predictive of long-term protective immunity are ing time intervals after BMT. In other studies 5,15 chronic GVHD did not influence response to TT vaccination. obtained with both vaccination schedules.
The present trial used adult HLA-matched sibling BMT In this study, a correlation of the anti-TT antibody concentration after BMT with the patient's own pretransplant recipients without T cell depletion. concentration after one injection of a similar TT vaccine. ports the concept that bone marrow recipients have adopted
